FDA approves Brexafemme (ibrexafungerp tablets) as the first oral non-azole treatment for vaginal yeast infections

Approval of this novel oral antifungal, with mechanism of action linked to glucan synthase inhibition, which is fungicidal against Candida species, was supported by positive results from two phase 3, placebo-controlled, studies (VANISH-303 and VANISH-306).

Source:

Biospace Inc.